Atai Life Sciences N.V.
General ticker "ATAI" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $504.7M (TTM average)
Atai Life Sciences N.V. follows the US Stock Market performance with the rate: 53.8%.
Estimated limits based on current volatility of 3.5%: low 3.91$, high 4.19$
Factors to consider:
- Total employees count: 63 (-24.1%) as of 2024
- Top business risk factors: Need for additional capital, Dependence on key products, Regulatory and compliance, Cybersecurity threats, Investment company act risk
- Current price 105.1% above estimated high
- Earnings for 9 months up through Q3 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.01$, 2.15$]
- 2025-12-31 to 2026-12-31 estimated range: [0.97$, 2.08$]
Financial Metrics affecting the ATAI estimates:
- Positive: with PPE of -1.3 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -41.36 <= 0.33
- Positive: Investing cash flow per share per price, % of 29.69 > -0.66
- Positive: Interest expense per share per price, % of 1.57 <= 3.41
- Positive: Shareholder equity ratio, % of 72.97 > 63.39
Short-term ATAI quotes
Long-term ATAI plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 |
|---|---|---|
| Operating Revenue | $0.31MM | $0.31MM |
| Operating Expenses | $125.78MM | $103.00MM |
| Operating Income | $-125.47MM | $-102.69MM |
| Non-Operating Income | $82.59MM | $-47.71MM |
| Interest Expense | $2.66MM | $3.12MM |
| R&D Expense | $62.20MM | $55.45MM |
| Income(Loss) | $-42.88MM | $-150.41MM |
| Taxes | $1.02MM | $-0.36MM |
| Profit(Loss)* | $-40.22MM | $-149.27MM |
| Stockholders Equity | $242.96MM | $116.30MM |
| Assets | $293.48MM | $159.39MM |
| Operating Cash Flow | $-84.12MM | $-82.44MM |
| Capital expenditure | $0.59MM | $0.10MM |
| Investing Cash Flow | $-53.30MM | $59.17MM |
| Financing Cash Flow | $-8.36MM | $5.37MM |
| Earnings Per Share** | $-0.25 | $-0.93 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.